Cochlear Implantation in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a neuroimmunologic demyelinating disorder that may present with central or peripheral sensorineural hearing loss (SNHL). This case describes a 43-year-old female with MOGAD and profound right-sided SNHL who did not improve with neuroimmunologic therapy. Additional immunologic and radiographic workup was unrevealing....

Continue reading at PubMed →

No practice change warranted from a single case, but cochlear implantation may be a viable option for MOGAD patients with severe sensorineural hearing loss (nerve-related hearing loss); clinicians should be aware of this rare association and document outcomes.

MOGAD is an emerging demyelinating diagnosis increasingly recognized as a cause of sensorineural hearing loss; this case expands the known candidacy landscape for cochlear implantation to include autoimmune demyelinating etiologies.

1. 01First or very rare documented case of cochlear implantation in a MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease) patient.
2. 02MOGAD is a demyelinating (nerve-sheath damaging) autoimmune disorder that can cause sensorineural hearing loss.
3. 03Published in Clinical Case Reports (DOI: 10.1002/ccr3.73690).
4. 04Case report design limits generalizability; outcomes for this specific patient are not detailed in the available description.
5. 05Raises awareness of MOGAD as a differential diagnosis in unexplained sensorineural hearing loss.

PMID

42846657

DOI

10.1002/ccr3.73690.

Journal

Clinical Case Reports

Publication type

case_report

Evidence level

4

Sample size

1

Population

Single patient with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and sensorineural hearing loss

Intervention

Cochlear implantation in a patient with MOGAD-associated sensorineural hearing loss